Kristin Van Goor

Company: Takeda Pharmaceutical

Job title: Head Executive Director, , Global Regulatory Policy & Innovation (US)

Seminars:

12:00 PM Panel Discussion: Defining Surrogate Endpoints for Rare & Genetic Kidney Disease 12:00 pm

Current regulatory perspectives on surrogate endpoints such as proteinuria in rare kidney diseases Industry perspectives on balancing the need for a 'registrable' surrogate endpoint with the goal of achieving a 'clinically compelling' outcome for patients Patient views on the use of surrogate endpoints in clinical trialsRead more

day: Conference Day 1